A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants with Graves’ Disease (GD)
This research is looking at a new treatment called Batoclimab for people with Graves' disease. Graves' disease is an autoimmune condition where the body mistakenly attacks the thyroid gland, making it produce too much thyroid hormone. This study is in an early stage (Phase II), meaning it's exploring whether Batoclimab is safe and effective. Researchers will check if people taking Batoclimab can get their thyroid hormone levels (FT3 and FT4) back to normal, or even a bit lower, without having to increase their usual medication for Graves' disease over a 24-week period. They will also look at whether people can reduce or stop their existing medication while maintaining normal hormone levels. Anyone aged 18 or over, male or female, might be able to take part.
Auf einen Blick
Worum geht es in dieser Studie?
This study is looking into a new medication called Batoclimab for a condition called Graves' disease. Graves' disease happens when your body's immune system attacks your thyroid gland, making it produce too much thyroid hormone. This can lead to symptoms like anxiety, weight loss, and a fast heartbeat. Current treatments help manage these symptoms, but researchers are always looking for new ways to help people.
The main goal of this study is to see if Batoclimab is safe to use and if it can help get your thyroid hormone levels back to a healthy range. Specifically, the researchers want to know if people taking Batoclimab can get their FT3 and FT4 hormone levels normal, or even slightly below normal, within 24 weeks, without needing to increase their usual thyroid medication. This is important because it could mean better control of the disease with less reliance on existing treatments.
The study will also look at other important things. For example, they'll check if people can reduce their current thyroid medication by half, or even stop it completely, while still keeping their hormone levels normal or low after 24 weeks. This early-stage study (Phase II) is a crucial step in understanding if Batoclimab could be a helpful new option for people living with Graves' disease.
Wichtige Erkenntnisse
- This study is testing a new medication, Batoclimab, for Graves' disease.
- It aims to see if Batoclimab can help normalise thyroid hormone levels.
- The study hopes to find out if participants can reduce or stop their current thyroid medications.
- It's an early-stage study (Phase II) focusing on safety and initial effectiveness.
- Participation involves regular clinic visits for 24 weeks plus follow-up.
- Anyone 18 years or older with Graves' disease may be eligible.
Wer könnte berechtigt sein?
To be considered for this study, you must be an adult, aged 18 years or older. This study is open to both men and women.
The research team will have a more detailed list of who can and cannot join the study. For instance, they might need to check your medical history, current medications, and other health conditions to make sure the study is safe and right for you.
It's important to discuss your full medical history with the study doctors to see if you meet all the requirements. They will explain everything clearly if you are interested in taking part.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Have you been diagnosed with Graves' disease?
- Können Sie regelmäßige Kliniktermine wahrnehmen?
- Are you comfortable with receiving a new, experimental medication?
- Do you understand the study involves blood tests and close monitoring?
Was beinhaltet die Teilnahme?
Taking part in this study would involve regular visits to the clinic over a period of 24 weeks. During these visits, you would receive the new medication, Batoclimab. The exact way you receive the medication (e.g., injection, tablets) would be explained by the study team. You would also have blood tests to check your thyroid hormone levels (FT3 and FT4) and to monitor your general health and watch for any side effects. You would also need to keep track of any other medications you are taking, especially your usual Graves' disease medication, as the study will monitor if its dose can be reduced. After the 24-week treatment period, there will be follow-up appointments to continue monitoring your health. The total duration of your involvement, including follow-up, would be fully explained by the study team.
Potenzielle Risiken und Vorteile
Standorte (1)
- —UnbestätigtDeutschland
Häufige Fragen
What is Graves' disease?
Graves' disease is a condition where your immune system attacks your thyroid gland, causing it to produce too much thyroid hormone. This can make you feel anxious, lose weight, and have a fast heart rate.
What is Batoclimab?
Batoclimab is a new medication being tested to see if it can help manage Graves' disease by bringing thyroid hormone levels back to normal.
Wie lange wird die Studie dauern?
The main treatment period for the study is 24 weeks, during which your health and hormone levels will be closely monitored. There will also be follow-up appointments after this period.
Will I still take my regular Graves' disease medication?
Yes, you will likely continue your regular medication, but the study will observe if your dose can be reduced or stopped over time while taking Batoclimab.
Is this medicine approved for general use?
No, Batoclimab is still in the research phase (Phase II) and is not yet approved for general use. Its safety and effectiveness are still being carefully studied.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.